2595308-10-2

XRD-0394 (3-10 mg/kg) via oral gavage 45 minutes prior to focal radiotherapy of 0 or 10 Gy and tumors are harvested for target inhibition assessment 1 hour after irradiation, XRD-0394 inhibits the activities of both DNA-PK and ATM kinases in tumors in vivo^[1].
Pharmacokinetic analyses show that 10 mg/kg XRD-0394 (oral gavage) resulted in plasma concentration of 840-1,125 ng/mL (1.6-2.1 mM) for 4 hours before declining to undetectable levels by 24 hours in mice^[1].